BOSSI, ELISA
Distribuzione geografica
Continente | # |
---|---|
NA - Nord America | 103 |
EU - Europa | 72 |
AS - Asia | 16 |
AF - Africa | 2 |
OC - Oceania | 1 |
SA - Sud America | 1 |
Totale | 195 |
Nazione | # |
---|---|
US - Stati Uniti d'America | 100 |
IT - Italia | 34 |
FR - Francia | 13 |
DE - Germania | 6 |
IE - Irlanda | 6 |
CN - Cina | 5 |
PT - Portogallo | 4 |
CA - Canada | 3 |
FI - Finlandia | 2 |
GB - Regno Unito | 2 |
IL - Israele | 2 |
IN - India | 2 |
NL - Olanda | 2 |
RO - Romania | 2 |
AE - Emirati Arabi Uniti | 1 |
AU - Australia | 1 |
CL - Cile | 1 |
GH - Ghana | 1 |
IQ - Iraq | 1 |
JP - Giappone | 1 |
RU - Federazione Russa | 1 |
SG - Singapore | 1 |
TR - Turchia | 1 |
TW - Taiwan | 1 |
VN - Vietnam | 1 |
ZA - Sudafrica | 1 |
Totale | 195 |
Città | # |
---|---|
Seattle | 10 |
Fairfield | 9 |
Houston | 8 |
Milan | 8 |
Santa Cruz | 8 |
Columbus | 7 |
Woodbridge | 7 |
Cambridge | 6 |
Dublin | 6 |
Buffalo | 5 |
Ashburn | 4 |
Rio de Mouro | 4 |
Shanghai | 4 |
Wilmington | 4 |
Frankfurt am Main | 3 |
Modena | 3 |
Toronto | 3 |
Ahi'ezer | 2 |
Amsterdam | 2 |
Boardman | 2 |
Bologna | 2 |
Carate Brianza | 2 |
Casorate Primo | 2 |
Chennai | 2 |
Los Angeles | 2 |
Rome | 2 |
San Francisco | 2 |
Seveso | 2 |
Turin | 2 |
Ankara | 1 |
Brisbane | 1 |
Bucharest | 1 |
Chicago | 1 |
Clearwater | 1 |
Erbil | 1 |
Gunzenhausen | 1 |
Hanoi | 1 |
Helsinki | 1 |
Henderson | 1 |
Indiana | 1 |
Kyoto | 1 |
Lappeenranta | 1 |
Las Vegas | 1 |
Lecce | 1 |
Lombard | 1 |
Malnate | 1 |
Marburg | 1 |
Monza | 1 |
Muizenberg | 1 |
New York | 1 |
Phoenix | 1 |
Prad am Stilfser Joch | 1 |
Riva | 1 |
Saint Petersburg | 1 |
Satu Mare | 1 |
Shulin District | 1 |
Singapore | 1 |
Tower Hamlets | 1 |
University Park | 1 |
Veniano | 1 |
Totale | 154 |
Nome | # |
---|---|
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization, file e39773b6-422d-35a3-e053-3a05fe0aac26 | 112 |
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia, file 5c471a21-cb11-4602-b96a-0a53c519def4 | 25 |
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706), file 5e456eae-4aaf-4615-9e27-02321f774770 | 22 |
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi, file ea09c0e1-ca76-4b9e-834a-6874da71604d | 21 |
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas, file 01194b51-9a89-4815-a965-374df2b4d001 | 19 |
Totale | 199 |
Categoria | # |
---|---|
all - tutte | 726 |
article - articoli | 0 |
book - libri | 0 |
conference - conferenze | 0 |
curatela - curatele | 0 |
other - altro | 0 |
patent - brevetti | 0 |
selected - selezionate | 0 |
volume - volumi | 0 |
Totale | 726 |
Totale | Lug | Ago | Sett | Ott | Nov | Dic | Gen | Feb | Mar | Apr | Mag | Giu | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019/2020 | 23 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 5 | 4 | 4 | 3 | 0 |
2020/2021 | 35 | 4 | 1 | 3 | 1 | 2 | 2 | 5 | 3 | 3 | 2 | 5 | 4 |
2021/2022 | 23 | 1 | 0 | 3 | 1 | 2 | 1 | 0 | 3 | 1 | 1 | 8 | 2 |
2022/2023 | 27 | 2 | 3 | 9 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 5 | 2 |
2023/2024 | 91 | 4 | 3 | 6 | 7 | 6 | 11 | 14 | 13 | 8 | 6 | 13 | 0 |
Totale | 199 |